Benzinga | Aug 9, 2021 08:12AM EDT

Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN

Alimera Sciences Europe Limited ("Alimera"), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited ("Tanner") announced today the initiation of a Named Patient Program for ILUVIEN(r) (fluocinolone acetonide intravitreal implant) 0.19 mg globally for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).



The agreement names Tanner as the exclusive provider of ILUVIEN in specific countries outside of the United States on a named-patient basis where the product is not commercially available for patients with DME and NIU-PS.

"Alimera is excited to partner with Tanner to offer additional distribution of ILUVIEN to patients globally," said Rick Eiswirth, Alimera's President and Chief Executive Officer. "This program will potentially help support patients with diabetic macular edema and non-infectious posterior uveitis who would otherwise not have access to a long-term option and will continue Alimera's commitment to physicians and their patients with diseases of the retina."

"We are proud to work with Alimera to make ILUVIEN available to patients in countries where it is not commercially available," said Banks Bourne, Chairman and Founder of Tanner Pharma Group. "This partnership reflects the type of company and innovative product Tanner strives to offer."